SCHEMBL1374853

SCHEMBL1374853

N[C@@H](CCC(=O)NCCO)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 3/20 0.52
SLC1A2 P43004 2/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GSR P00390 1/20 0.52
CYP1A2 P05177 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
GRIA4 P48058 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52
GRIK2 Q13002 1/20 0.52
GRIK3 Q13003 1/20 0.52
GRIN2B Q13224 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1512875 1.00 SLC1A1 (0.52) SLC1A1SLC1A2GRM8GRM6GRIN2D
Phosphoric Acid SCHEMBL10888209 0.93 OTC (0.54) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL29590846 0.90 SLC1A1 (0.58) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL18637013 0.89 OTC (0.53) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL1372555 0.89 OTC (0.53) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL4899060 0.87 OTC (0.51) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL8627837 0.87 OTC (0.51) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL1768540 0.85 GSR (0.52) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL8041593 0.85 GRM8 (0.63) SLC1A1SLC1A2GRM8GRM6GRIN2D
SCHEMBL8041596 0.85 GRM8 (0.63) SLC1A1SLC1A2GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9101662-B2 Compositions with modulating agents FOAMIX PHARMACEUTICALS LTD. (IL) 2015-08-11 US claimed
US-8795693-B2 Compositions with modulating agents FOAMIX LTD. (IL) 2014-08-05 US claimed
EP-2097065-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS Foamix Ltd. (IL) 2009-09-09 EP claimed
WO-2008152444-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS FOAMIX LTD. (US) 2008-12-18 WO claimed
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions FOAMIX LTD. (IL) 2008-08-28 US claimed
EP-0941123-B1 NUCLEIC ACID COMPLEXED WITH CATIONIC POLYMER USEFUL FOR GENE THERAPY HYBRID SYSTEMS LTD (GB) 2002-06-12 EP claimed
EP-0804246-B1 DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN EUROP ECONOMIC COMMUNITY (LU) 2000-05-17 EP claimed
EP-0941123-A2 DELIVERY OF NUCLEIC ACID MATERIAL TO TARGET CELLS IN BIOLOGICAL SYSTEMS SCHACHT, Etienne Honoré (BE) 1999-09-15 EP claimed
WO-1998019710-A2 DELIVERY OF NUCLEIC ACID MATERIAL TO TARGET CELLS IN BIOLOGICAL SYSTEMS SCHACHT ETIENNE HONORE (BE) 1998-05-14 WO claimed
EP-4667483-A1 HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE JCR Pharmaceuticals Co., Ltd. (JP) 2025-12-24 EP disclosed
WO-2025096734-A1 MICROCAPSULES FMC CORPORATION (US) 2025-05-08 WO disclosed
CN-119234640-A Selenium-enriched millet and production method thereof 中国农业大学 2025-01-03 CN disclosed
WO-2024172166-A1 HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE JCRファーマ株式会社 2024-08-22 WO disclosed
WO-2024126857-A1 SYNTHESIS OF POLY(AMINO ACIDS) UNIVERSITY OF LEEDS (GB) 2024-06-20 WO disclosed
EP-0910351-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-28 EP disclosed
EP-0907666-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-14 EP disclosed
WO-1998019710-A2 DELIVERY OF NUCLEIC ACID MATERIAL TO TARGET CELLS IN BIOLOGICAL SYSTEMS SCHACHT ETIENNE HONORE (BE) 1998-05-14 WO disclosed
WO-1997049736-A2 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
WO-1997049387-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
EP-0308983-A2 NMR imaging with Mn(II) coordination compositions SALUTAR, INC. (US) 1989-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions CUTA, SLTM, SMO SLC1A1 4373/4885SLC1A2 4428/4885GRM8 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.